Armistice Capital, LLC Acquires 7.05% Stake in BioXcel Therapeutics, Inc. (BTAI)

On May 15, 2026, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G disclosing a new 7.05% ownership stake in BioXcel Therapeutics, Inc. (BTAI). The reporting persons beneficially own 1,910,076 shares of common stock, which are held directly by the Armistice Capital Master Fund Ltd. As the investment manager of the Master Fund, Armistice Capital, LLC exercises shared voting and dispositive power over these securities. The filing indicates that the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This position represents a significant increase from a previous 0% ownership level reported, crossing the 5% threshold that triggers public disclosure requirements. The Master Fund, as an investment advisory client, retains the right to receive dividends and proceeds from the sale of these shares. The event triggering this filing occurred on March 31, 2026.